Ravidasvir

Ravidasvir
Clinical data
Other names	PPI-668
ATC code	J05AP13 (WHO) ;
Identifiers
	IUPAC name (2S)-2-{[Hydroxy(methoxy)methylidene]amino}-1-[(2S)-2-[5-(6-{2-[(2S)-1-[(2S)-2-{[hydroxy(methoxy)methylidene]amino}-3-methylbutanoyl]pyrrolidin-2-yl]-1H-1,3-benzodiazol-6-yl}naphthalen-2-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methylbutan-1-one;
CAS Number	1242087-93-9;
PubChem CID	52918888;
ChemSpider	31141686;
UNII	AL3G001BI8;
KEGG	D12744;
ChEMBL	ChEMBL3121849;
Chemical and physical data
Formula	C42H50N8O6
Molar mass	762.912 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C(=O)N1CCC[C@H]1C2=NC3=C(N2)C=C(C=C3)C4=CC5=C(C=C4)C=C(C=C5)C6=CN=C(N6)[C@@H]7CCCN7C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC;
	InChI InChI=1S/C42H50N8O6/c1-23(2)35(47-41(53)55-5)39(51)49-17-7-9-33(49)37-43-22-32(46-37)29-14-13-25-19-26(11-12-27(25)20-29)28-15-16-30-31(21-28)45-38(44-30)34-10-8-18-50(34)40(52)36(24(3)4)48-42(54)56-6/h11-16,19-24,33-36H,7-10,17-18H2,1-6H3,(H,43,46)(H,44,45)(H,47,53)(H,48,54)/t33-,34-,35-,36-/m0/s1; Key:LCHMHYPWGWYXEL-ZYADHFCISA-N;

Ravidasvir (PPI-668) is an investigational NS5A inhibitor (by Pharco Pharmaceuticals) in clinical trials for chronic hepatitis C genotype 4.^[1]

It is on the World Health Organization's List of Essential Medicines.^[2]

Preliminary clinical trial results were announced in Nov 2015.^[3] In April 2017, press reports stated that a combination treatment involving ravidasvir and sofosbuvir had achieved a 97% clearup rate against hepatitis C in a clinical trial conducted in Malaysia and Thailand, and 100% in another conducted in Egypt.^[4] It has been granted conditional registration by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia.^[5]^[6]

References

^ Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
^ "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. 24 November 2015.
^ Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian.
^ "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia" (PDF).
^ "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Retrieved 10 August 2021.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] Clinical trial number NCT02371408 for "Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4" at ClinicalTrials.gov

[WHO23rd-2] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[3] "Good Results for Sovaldi and Ravidasvir Treating Hepatitis C Genotype 4". Hepatitis Magazine. 24 November 2015.

[4] Kollewe J (13 April 2018). "Non-profit's $300 hepatitis C cure as effective as $84,000 alternative". The Guardian.

[5] "List of new products approved by the National Pharmaceutical Regulatory Agency (NPRA) of Malaysia" (PDF).

[6] "First hepatitis C treatment developed through South-South cooperation registered in Malaysia | DNDi". dndi.org. 14 June 2021. Retrieved 10 August 2021.

[1]

[2]

[3]

[4]

[5]

[6]